Immune Therapeutics, Inc. (IMUN) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Immune Therapeutics, Inc. (IMUN) es una empresa del sector Healthcare valorada en 0. Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Immune Therapeutics, Inc. (IMUN) Resumen de Asistencia Médica y Tuberías
Immune Therapeutics, Inc., formerly TNI BioTech, operates within the biotechnology sector but currently lacks significant operational activity. The company, headquartered in Orlando, Florida, focuses on the healthcare industry, though its current business activities are minimal, presenting a speculative investment profile.
Tesis de Inversión
Investing in Immune Therapeutics, Inc. (IMUN) presents a highly speculative opportunity due to the company's current lack of significant operations. With a market capitalization of $0.01 billion and a negative price-to-earnings ratio, traditional valuation metrics offer limited insight. The company's beta of 0.26 suggests lower volatility compared to the market. Potential catalysts include the announcement of new strategic initiatives or the acquisition of assets that could revitalize the company's operations. However, the primary risk lies in the uncertainty surrounding the company's future direction and its ability to generate revenue. Investors should carefully consider the speculative nature of this investment and the potential for significant losses.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.01 billion, indicating a micro-cap company.
- Negative P/E ratio due to the absence of significant operations and earnings.
- Beta of 0.26, suggesting lower volatility compared to the broader market.
- No dividend yield, consistent with companies in a developmental or transitional phase.
- Change of name from TNI BioTech to Immune Therapeutics, Inc. in October 2014, signaling a strategic shift.
Competidores y Pares
Fortalezas
- Potential for strategic repositioning within the biotechnology sector.
- Name recognition associated with immune-related therapies.
- Low beta suggests lower volatility.
- Existing corporate structure allows for rapid deployment of new strategies.
Debilidades
- Lack of significant operations.
- Unclear strategic direction.
- Limited financial resources.
- Absence of revenue generation.
Catalizadores
- Upcoming: Announcement of new strategic initiatives or partnerships.
- Upcoming: Acquisition of biotechnology assets or companies.
- Ongoing: Potential for breakthroughs in immune-related therapies.
- Ongoing: Changes in the regulatory landscape for biotechnology companies.
- Ongoing: Developments in the broader healthcare sector.
Riesgos
- Potential: Lack of significant operations may lead to delisting or dissolution.
- Potential: Intense competition within the biotechnology sector.
- Potential: Regulatory hurdles and clinical trial risks.
- Ongoing: Uncertainty surrounding future funding and capital raising.
- Ongoing: Dependence on external factors and market conditions.
Oportunidades de crecimiento
- Strategic Acquisition: Immune Therapeutics could pursue strategic acquisitions of promising biotechnology assets or companies. This would provide an immediate boost to its operational capabilities and pipeline. The market for biotech acquisitions is robust, with numerous opportunities to acquire undervalued assets. Timeline: Within the next 1-2 years.
- Partnerships and Collaborations: Forming partnerships with larger pharmaceutical companies or research institutions could provide Immune Therapeutics with access to funding, expertise, and resources. Collaborative agreements are common in the biotechnology industry and can accelerate the development and commercialization of new therapies. Timeline: Ongoing.
- Focus on Niche Therapeutic Areas: Immune Therapeutics could focus on developing therapies for niche therapeutic areas with unmet medical needs. This would allow the company to differentiate itself from larger competitors and potentially achieve faster regulatory approval. The market for orphan drugs and rare disease therapies is growing rapidly. Timeline: Within the next 3-5 years.
- Development of Novel Drug Delivery Systems: Investing in the development of novel drug delivery systems could enhance the efficacy and safety of existing therapies. This would create a competitive advantage and potentially attract partnerships with pharmaceutical companies seeking to improve their product portfolios. The market for drug delivery technologies is expanding. Timeline: Within the next 3-5 years.
- Capitalizing on Immunotherapy Advancements: Given its name, Immune Therapeutics could explore opportunities in the rapidly expanding field of immunotherapy. This could involve developing novel immunotherapies for cancer or other diseases, or partnering with companies that have promising immunotherapy candidates. The immunotherapy market is experiencing significant growth. Timeline: Ongoing.
Oportunidades
- Strategic acquisitions of promising biotechnology assets.
- Partnerships with larger pharmaceutical companies.
- Focus on niche therapeutic areas with unmet medical needs.
- Development of novel drug delivery systems.
Amenazas
- Intense competition within the biotechnology sector.
- Regulatory hurdles and clinical trial risks.
- Uncertainty surrounding future funding and capital raising.
- Potential for obsolescence of existing technologies.
Ventajas competitivas
- Currently, there is no discernible economic moat due to the lack of significant operations.
- Potential future moat could be established through intellectual property, strategic partnerships, or unique therapeutic approaches.
- Moat development dependent on successful execution of strategic initiatives.
Acerca de IMUN
Immune Therapeutics, Inc., originally established as TNI BioTech, underwent a name change in October 2014, signaling a strategic shift that has yet to materialize into substantial operational activities. Headquartered in Orlando, Florida, the company exists within the biotechnology sector, a field known for its high-risk, high-reward potential. However, Immune Therapeutics, Inc. presently does not have significant operations, indicating a company in a developmental or transitional phase. The company's history suggests a potential pivot towards immune-related therapies, aligning with the biotechnology industry's focus on innovative healthcare solutions. Despite this, the absence of current operations raises questions about the company's strategic direction and future prospects. The company's evolution from TNI BioTech to Immune Therapeutics suggests an intention to capitalize on the growing interest in immunotherapy and related fields, but the lack of tangible business activities makes it difficult to assess its competitive positioning and long-term viability. The company's future hinges on its ability to develop and commercialize viable products or services within the biotechnology sector.
Qué hacen
- Formerly known as TNI BioTech, Inc.
- Changed its name to Immune Therapeutics, Inc. in October 2014.
- Headquartered in Orlando, Florida.
- Operates within the healthcare sector.
- Focuses on the biotechnology industry.
- Currently does not have significant operations.
Modelo de Negocio
- Currently, the business model is not clearly defined due to the lack of significant operations.
- Potentially focused on developing or acquiring immune-related therapies.
- Future revenue generation dependent on strategic initiatives and partnerships.
Contexto de la Industria
Immune Therapeutics, Inc. operates within the biotechnology sector, an industry characterized by intense research and development, high regulatory hurdles, and significant growth potential. The global biotechnology market is projected to reach trillions of dollars by 2030, driven by advancements in genomics, personalized medicine, and immunotherapy. However, the industry is also highly competitive, with numerous companies vying for market share. Immune Therapeutics, Inc.'s lack of significant operations places it at a disadvantage compared to established players like BNOEF (BioNtech SE), CRBKF (CARB-X), FWPAY (Forward Pharma A/S), HBCNF (Hope Biosciences), and IPCIF (InPro Biotechnology Inc.), which have active research programs and commercialized products.
Clientes Clave
- Not applicable due to the lack of significant operations.
- Potential future customers could include patients, healthcare providers, and pharmaceutical companies.
- Customer base dependent on the development and commercialization of specific products or services.
Finanzas
Gráfico e información
Precio de la acción de Immune Therapeutics, Inc. (IMUN): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 mar 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para IMUN.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para IMUN.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de IMUN en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Noreen M. Griffin
CEO
Noreen M. Griffin serves as the CEO of Immune Therapeutics, Inc. Information regarding her detailed career history, education, and previous roles is not available in the provided data. Further research would be required to provide a comprehensive overview of her professional background and credentials.
Historial: Due to the lack of significant operations at Immune Therapeutics, Inc., it is difficult to assess Noreen M. Griffin's track record in terms of key achievements, strategic decisions, and company milestones under her leadership. Her tenure has not yet been marked by significant operational or financial progress.
Información del mercado OTC de IMUN
The OTC Other tier represents the lowest tier of the OTC market, indicating that Immune Therapeutics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may be subject to greater risks.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in IMUN.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- OTC Other tier companies are subject to less regulatory oversight.
- The absence of significant operations raises concerns about the company's viability.
- Potential for fraud or manipulation is higher in the OTC market.
- Verify the company's financial statements and SEC filings (if available).
- Research the background and experience of the company's management team.
- Assess the company's business plan and strategic outlook.
- Evaluate the company's competitive positioning within the biotechnology sector.
- Determine the company's sources of funding and capital raising plans.
- Monitor news and press releases for any updates on the company's operations.
- Consult with a qualified financial advisor before making any investment decisions.
- The company's registration with the SEC (if applicable).
- The presence of a qualified management team.
- Any patents or intellectual property owned by the company.
- Strategic partnerships or collaborations with reputable organizations.
- Independent audits of the company's financial statements (if available).
Acciones de Immune Therapeutics, Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar IMUN?
Immune Therapeutics, Inc. (IMUN) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Potential for strategic repositioning within the biotechnology sector.. Riesgo principal a monitorear: Potential: Lack of significant operations may lead to delisting or dissolution.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de IMUN?
IMUN actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de IMUN?
Los precios de IMUN se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre IMUN?
La cobertura de analistas para IMUN incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en IMUN?
Las categorías de riesgo para IMUN incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Lack of significant operations may lead to delisting or dissolution.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de IMUN?
La relación P/E para IMUN compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está IMUN sobrevalorada o infravalorada?
Determinar si Immune Therapeutics, Inc. (IMUN) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de IMUN?
Immune Therapeutics, Inc. (IMUN) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is limited due to the company's lack of significant operations and limited public disclosure.
- AI analysis pending for IMUN.